These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 34040351)

  • 1. Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study.
    Wang X; Wang Y; Yao F; Chen S; Hou Y; Zheng Z; Luo J; Qiu B; Li Z; Wang Y; Wu Z; Lan J; Chen C
    Drug Des Devel Ther; 2021; 15():2129-2141. PubMed ID: 34040351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective.
    Barrasa H; Soraluce A; Usón E; Sainz J; Martín A; Sánchez-Izquierdo JÁ; Maynar J; Rodríguez-Gascón A; Isla A
    Int J Infect Dis; 2020 Apr; 93():329-338. PubMed ID: 32112965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients.
    Dong H; Xie J; Wang T; Chen L; Zeng X; Sun J; Wang X; Dong Y
    Int J Antimicrob Agents; 2016 Sep; 48(3):259-64. PubMed ID: 27474469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment.
    Barrasa H; Soraluce A; Isla A; Martín A; Maynar J; Canut A; Sánchez-Izquierdo JA; Rodríguez-Gascón A
    J Crit Care; 2019 Apr; 50():69-76. PubMed ID: 30496913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of meropenem dosage in the critically ill population based on renal function.
    Crandon JL; Ariano RE; Zelenitsky SA; Nicasio AM; Kuti JL; Nicolau DP
    Intensive Care Med; 2011 Apr; 37(4):632-8. PubMed ID: 21136037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and Pharmacodynamic Analysis of Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Imipenem.
    Li Z; Bai J; Wen A; Shen S; Duan M; Li X
    Clin Ther; 2020 Aug; 42(8):1564-1577.e8. PubMed ID: 32741646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linezolid extracorporeal removal during haemodialysis with high cut-off membrane in critically ill patients.
    Villa G; Cassetta MI; Tofani L; Valente S; Chelazzi C; Falsini S; De Gaudio AR; Novelli A; Ronco C; Adembri C
    Int J Antimicrob Agents; 2015 Oct; 46(4):465-8. PubMed ID: 26315198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance?
    Ollivier J; Carrié C; d'Houdain N; Djabarouti S; Petit L; Xuereb F; Legeron R; Biais M; Breilh D
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration.
    Roger C; Muller L; Wallis SC; Louart B; Saissi G; Lipman J; Lefrant JY; Roberts JA
    J Antimicrob Chemother; 2016 Feb; 71(2):464-70. PubMed ID: 26538503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosage Strategy of Linezolid According to the Trough Concentration Target and Renal Function in Chinese Critically Ill Patients.
    Wu F; Zhang XS; Dai Y; Zhou ZY; Zhang CH; Han L; Xu FM; Wang YX; Shi DW; Lin GY; Yu XB; Chen F
    Front Pharmacol; 2022; 13():844567. PubMed ID: 35479324
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.
    Minichmayr IK; Schaeftlein A; Kuti JL; Zeitlinger M; Kloft C
    Clin Pharmacokinet; 2017 Jun; 56(6):617-633. PubMed ID: 27753002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.
    Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis.
    Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2016 Nov; 48(5):542-546. PubMed ID: 27771187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia.
    Xie F; Mantzarlis K; Malliotakis P; Koulouras V; Degroote S; Koulenti D; Blot S; Boussery K; Van Bocxlaer J; Colin P;
    J Antimicrob Chemother; 2019 Mar; 74(3):667-674. PubMed ID: 30535122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
    O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy.
    Ide T; Takesue Y; Ikawa K; Morikawa N; Ueda T; Takahashi Y; Nakajima K; Takeda K; Nishi S
    Int J Antimicrob Agents; 2018 May; 51(5):745-751. PubMed ID: 29425834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.
    Millard J; Pertinez H; Bonnett L; Hodel EM; Dartois V; Johnson JL; Caws M; Tiberi S; Bolhuis M; Alffenaar JC; Davies G; Sloan DJ
    J Antimicrob Chemother; 2018 Jul; 73(7):1755-1762. PubMed ID: 29584861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?
    Udy AA; Lipman J; Jarrett P; Klein K; Wallis SC; Patel K; Kirkpatrick CM; Kruger PS; Paterson DL; Roberts MS; Roberts JA
    Crit Care; 2015 Jan; 19(1):28. PubMed ID: 25632974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes.
    Vu DH; Nguyen DA; Delattre IK; Ho TT; Do HG; Pham HN; Dao XC; Tran NT; Nguyen GB; Van Bambeke F; Tulkens PM; Nguyen HA
    Int J Antimicrob Agents; 2019 Dec; 54(6):702-708. PubMed ID: 31600554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.